Scholar Rock Holding Investor Relations Material

Scholar Rock Holding Corp is a biopharmaceutical company engaged in the discovery and development of innovative medicines for the treatment of serious diseases, with a focus on those in which signaling by protein growth factors plays a fundamental role. The company's research and development efforts include Apitegromab, an inhibitor of the activation of latent myostatin that has completed Phase 3 clinical trials for the treatment of spinal muscular atrophy, and SRK-181, which is in clinical trials for the treatment of cancers resistant to checkpoint inhibitor therapies. Scholar Rock is also developing a pipeline of novel product candidates aimed at transforming the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. cholar Rock Holding Corp is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.